BD1018
 | |
| Systematic (IUPAC) name | |
|---|---|
| (S)-2-[2-(3,4-dichlorophenyl)ethyl]octahydropyrrolo[1,2-a]pyrazine | |
| Clinical data | |
| Identifiers | |
| 150208-42-7 | |
| PubChem | CID 9796317 |
| ChemSpider | 7972083 |
| Chemical data | |
| Formula | C15H20Cl2N2 |
| 299.24 g/mol | |
|
SMILES
| |
| |
BD1018 or (S)-2-[2-(3,4-dichlorophenyl)ethyl]octahydropyrrolo[1,2-a]pyrazine is a selective sigma receptor ligand, with a reported binding affinity of Ki = 5 ± 0.7 nM for the sigma-1 receptor and approximately 10 times selectivity over the sigma-2 receptor.[1] Unlike its enantiomer, BD1031, BD1018 acts as a sigma receptor antagonist.[1]
Consistent with other reported sigma receptor antagonists, BD1018 deccreases the behavioural toxicity of cocaine in Swiss Webster mice.[1]
See also
References
- ↑ 1.0 1.1 1.2 Matsumoto RR, McCracken KA, Friedman MJ, Pouw B, De Costa BR, Bowen WD (2001). "Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice". Eur. J. Pharmacol. 419 (2-3): 163–74. doi:10.1016/s0014-2999(01)00968-2.